Plain-English translation of NCT07114601 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Neoplasms research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medicine called , which is a radioactive treatment designed to find and attack cancer cells that have a specific protein called GRPR. Researchers want to understand how safe this medication is, how well people tolerate it, and whether it can help slow or shrink several types of advanced cancer, including breast, colorectal, prostate, and stomach cancers. Some participants will receive this treatment alone, while others may receive it combined with standard cancer therapies.
Many advanced cancers are difficult to treat with existing therapies, and patients need new options. This medication targets a specific protein found on certain cancer cells, which may allow it to attack tumors more precisely while causing fewer side effects to healthy tissue.
You likely qualify if…
You likely don't qualify if…
You will receive the radioactive medication as an intravenous infusion (through an IV) during clinic visits over several months. The trial has different phases: some participants will receive the medication alone at escalating doses to find the safest amount, while others will receive it combined with their standard cancer drugs. You will have regular blood tests, imaging scans (CT or MRI), and clinic visits to monitor how the treatment is working and check for side effects. Your participation could last up to 36 weeks, or until your cancer progresses.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States